Pregene Out-Licenses India Rights for its CAR-T Therapy to Dr. Reddy's

Shenzhen Pregene Biopharma out-licensed Indian rights for its anti-BCMA CAR-T cell therapy to Dr. Reddy's Labs. Dr. Reddy's will make $5 million in upfront and milestone payments for the first indication of the therapy and $7.5 million for any additional indications. It will also pay double-digit royalties up to $150 million. Dr. Reddy's will be responsible for all development costs in India . In a China investigator-led trial, PRG1801 showed positive signs of efficacy and safety in 34 patients with relapsed/refractory multiple myeloma. More details.... Stock Symbol: (BSE: 500124) Share this with colleagues: // //